Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.

BACKGROUND The current study was conducted to evaluate the efficacy of paclitaxel, administered weekly or once every 3 weeks, in combination with oral estramustine phosphate (EMP) in patients with recurrent or refractory aggressive non-Hodgkin lymphoma (NHL). METHODS Between February 1996 and February 2001, 23 patients with recurrent NHL were enrolled… CONTINUE READING